{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Solid+Tumors&page=10",
    "query": {
      "condition": "Locally Advanced or Metastatic Solid Tumors",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 370,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Solid+Tumors&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Solid+Tumors&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T08:47:25.979Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Melanoma",
        "Metastasis",
        "Pleural Mesothelioma",
        "Renal Cell Carcinoma",
        "MSI-High",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer",
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Renal Cell Cancer",
        "Kidney Cancer",
        "Skin Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
        "ALK Genomic Tumor Aberrations"
      ],
      "interventions": [
        {
          "name": "Alintegimod",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2024-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362369"
    },
    {
      "nct_id": "NCT07524322",
      "title": "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "PIK3CA Mutation",
        "HER2- Negative Breast Cancer",
        "Advanced Breast Cancer",
        "Unresectable Solid Tumor",
        "Hormone Receptor Positive Tumor",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "RGT-490",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regor Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2026-06",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Houston, Texas • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07524322"
    },
    {
      "nct_id": "NCT06413680",
      "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Clear-Cell Renal-Cell Carcinoma (ccRCC)",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "REGN10597",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2024-09-23",
      "completion_date": "2030-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06413680"
    },
    {
      "nct_id": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Renal Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Nasopharyngeal Carcinoma",
        "Oropharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "INBRX-105 - PDL1x41BB antibody",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2019-01-30",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809624"
    },
    {
      "nct_id": "NCT01209143",
      "title": "A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Cancers"
      ],
      "interventions": [
        {
          "name": "Vismodegib",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Norethindrone/ethinyl estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2010-11",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2015-06-29",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Detroit, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209143"
    },
    {
      "nct_id": "NCT07488676",
      "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma",
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ASP546C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-05-04",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07488676"
    },
    {
      "nct_id": "NCT02453620",
      "title": "Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Breast Adenocarcinoma",
        "Invasive Breast Carcinoma",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood Sample",
          "type": "OTHER"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Entinostat",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2016-02-12",
      "completion_date": "2027-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 5,
      "location_summary": "Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02453620"
    },
    {
      "nct_id": "NCT07335497",
      "title": "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced / Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CR-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crescent Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2026-02-17",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07335497"
    },
    {
      "nct_id": "NCT03822117",
      "title": "Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor Malignancy"
      ],
      "interventions": [
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2019-10-17",
      "completion_date": "2022-03-29",
      "has_results": true,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 44,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822117"
    },
    {
      "nct_id": "NCT01973868",
      "title": "Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Regorafenib (Stivarga, BAY73-4506)",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab (ERBITUX)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2013-11-21",
      "completion_date": "2018-04-03",
      "has_results": false,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-10-14T08:47:25.979Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01973868"
    }
  ]
}